MSLP: New Independent Board Member

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


(b) On June 1, 2021, John Desmond, Chair of the Audit Committee, a member of the Nominating & Corporate Governance Committee, and a member of the Compensation Committee of the Board of Directors (the “Board”) of MusclePharm Corporation (the “Company”) notified the Board of his resignation effective immediately.



(d) Effective June 1, 2021, the Board appointed Paul Karr to serve as a director until the Company’s 2021 annual meeting of stockholders or his earlier death, resignation or removal. Mr. Karr will serve as the Chair of the Audit Committee, a member of the Nominating & Corporate Governance Committee, and a member of the Compensation Committee of the Board.



Mr. Karr will be compensated for his service as a director in accordance with the Company’s non-employee director compensation policy. The Company plans to enter into an indemnification agreement with Mr. Karr, which will provide him with indemnification in connection with his service as a member of the Board.



Item 7.01 Regulation FD Disclosure.


On June 1, 2021, the Company issued a press release regarding certain of the matters described in Item 5.02. That press release is furnished herewith as Exhibit 99.1.



The information included in this Current Report on Form 8-K under this Item 7.01 (including Exhibit 99.1) shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.